Norman Hardman
Vorstandsvorsitzender bei Oxalis Partners LLC
Profil
Norman Hardman currently works at Oxalis Partners LLC, as President & Chief Executive Officer from 2006 and Anosos Biotherapeutics LLC, as Chief Executive Officer.
Dr. Hardman also formerly worked at Amicus Therapeutics, Inc., as President & Chief Executive Officer from 2002 to 2004, Lifearc, as Chief Executive Officer from 2002 to 2003, ValiRx Plc, as Non-Executive Director, Chelsea Therapeutics International Ltd., as Independent Director from 2008 to 2012, Chelsea Therapeutics, Inc., as Director, AERES Biomedical Ltd., as Director, Enzon Pharmaceuticals, Inc., as Senior Vice President-Technology in 2003, gMed., Inc., as President & Chief Operating Officer, Onyx Pharmaceuticals, Inc., as Chief Operating Officer, Novartis AG, as Head-UK Research & Development Operations, and BASF Performance Products Ltd.
(United Kingdom), as Head-Research & Development.
Dr. Hardman received his doctorate degree from The University of Manchester and undergraduate degree from the University of London.
Aktive Positionen von Norman Hardman
| Unternehmen | Position | Beginn |
|---|---|---|
| Oxalis Partners LLC | Vorstandsvorsitzender | 01.05.2006 |
| Anosos Biotherapeutics LLC | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Norman Hardman
| Unternehmen | Position | Ende |
|---|---|---|
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Direktor/Vorstandsmitglied | 10.07.2012 |
| AMICUS THERAPEUTICS, INC. | Präsident | 01.05.2004 |
| ENZON PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.09.2003 |
Lifearc
 Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Präsident | 01.09.2003 |
AERES Biomedical Ltd.
 AERES Biomedical Ltd. Drugstore ChainsRetail Trade AERES Biomedical Ltd. develops therapeutic antibodies. The firm's products target debilitating and life-threatening illnesses, such as infectious, inflamatory and cardiovascular diseases. The company was founded on July 5, 1999 by Tarran Jones & David Copsey and is headquartered in Mill Hill, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Norman Hardman
| The University of Manchester | Doctorate Degree |
| University of London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| VALIRX PLC | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Private Unternehmen | 9 |
|---|---|
gMed., Inc.
 gMed., Inc. BiotechnologyHealth Technology gMed is engaged in providing physicians with information solutions to “Care Better” for their patients and practice. The company provides Digital Charting solutions for Gastroenterology and Cardiology designed to eliminate paper, increase revenues, decrease costs and enhance patient care at the medical office, ambulatory surgery center and hosptial. gMED was founded in 1997 and is located in Weston, FL. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
BASF Performance Products Ltd. (United Kingdom)
 BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom. | Process Industries |
| Chelsea Therapeutics, Inc. | Health Technology |
AERES Biomedical Ltd.
AERES Biomedical Ltd. Drugstore ChainsRetail Trade AERES Biomedical Ltd. develops therapeutic antibodies. The firm's products target debilitating and life-threatening illnesses, such as infectious, inflamatory and cardiovascular diseases. The company was founded on July 5, 1999 by Tarran Jones & David Copsey and is headquartered in Mill Hill, the United Kingdom. | Retail Trade |
Lifearc
Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Commercial Services |
| Oxalis Partners LLC | |
| Anosos Biotherapeutics LLC |
